<<Print>>

Ghana is poised to begin the local production of anti-snake venom, thanks to a Memorandum of Understanding (MOU) between Atlantic Lifescience Limited and Vins Bioproducts Limited.

This groundbreaking collaboration has the potential to revolutionize the healthcare landscape in the country and create economic opportunities.

The locally manufactured anti-snake venom by Atlantic Lifesciences is designed to be a polyvalent solution, capable of neutralizing the venoms of more than 19 different species of snakes. This critical feature is particularly valuable in cases where identifying the exact snake responsible for a bite is challenging.

One of the primary benefits of this initiative is the reduction of the burden on the Ghanaian government to continually import anti-snake venom. With local production, Ghana can enhance its self-sufficiency in healthcare resources.

Under the terms of the MOU, Vins Bioproducts will supply bulk quantities of anti-snake venom to Atlantic Lifesciences, facilitating the commencement of the fill and finish production in Ghana.

Siddharth Daga, the CEO of Vins Bioproducts, expressed optimism that this collaboration will not only elevate anti-snake vaccine production in Ghana and Africa but also generate employment opportunities, further contributing to the nation's economic growth.

"I am hopeful that, this collaboration will be an example of elevating anti-snake vaccine production not only in Ghana but the rest of Africa. It will also help us in building local capacity and create jobs for the local populace." He said


The Chief Executive Officer of Atlantic Lifesciences, Dhananjay Tripathi, indicated that Ghana would be the first country in West Africa to produce anti-snake venom for local use and export.

Dr. Delese Mimi Darko, Chief Executive Officer of the Food and Drugs Authority (FDA), emphasized the FDA's pivotal role in this endeavor. The FDA will provide essential regulatory support, including ensuring that local facilities and equipment for bulk manufacturing and filling meet international quality standards. Dr. Darko stated,

"The FDA will ensure product quality assurance through regular good manufacturing practice inspections and also monitor the safety of the products by using our robust advanced system."